Pipeline

November 9, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
OncoSec Medical CORVax12 DNA-encodable vaccine against SARS-CoV-2 IND approved by the FDA
Equillium itolizumab hospitalized COVID-19 patients with acute respiratory distress syndrome (ARDS) IND approved by FDA for phase 3 trial
Symvivo Corporation bacTRL-spike oral vaccine prevention of COVID-19 first patient dosed in phase 1 trial
RevImmune CYT107 (recombinant human Interleukin-7) patients critically ill with COVID-19 patient enrollment initiated in the U.S. in phase 2 trial
Humanigen lenzilumab prevention of cytokine storm in hospitalized patients with COVID-19 first patient dosed in phase 3 trial
Other Trials and Actions
enGene EG-70 Bacille Calmette-Guerin (BCG)-unresponsive nonmuscle-invasive bladder cancer IND approved by the FDA
InnoCare Pharma orelabrutinib multiple sclerosis IND approved by the FDA
Neuraly NLY01 Alzheimer’s disease IND approved by the FDA
OliX Pharmaceuticals OLX10010 adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery IND approved by the FDA
TaiGen Biotechnology TG-1000 influenza A and B IND approved by the FDA
Aligos Therapeutics ALG-000184 chronic hepatitis B virus first patient dosed in phase 1a/1b trial
BiomX BX002 inflammatory bowel disease first patient dosed in phase 1a trial
Synlogic SYNB8802 enteric hyperoxaluria first patient dosed in phase 1 trial
MindMed LSD microdose and experiential doses anxiety disorders completion of phase 1 trial
Q32 Bio ADX-914 autoimmune diseases first patient dosed in phase 1 trial
ADC Therapeutics camidanlumab tesirine (ADCT-301) in combination with pembrolizumab select advanced solid tumors first patients dosed in combination arm of phase 1b trial
Gritstone Oncology GRANITE and SLATE (neoantigen-based immunotherapies) historically cold (or non-immunogenic) tumor types first patients dosed in phase 2 expansion cohorts of phase 1/2 trials
Rubius Therapeutics RTX-240 acute myeloid leukemia first patient dosed in phase 1/2 trial
Novus Therapeutics AT-1501 amyotrophic lateral sclerosis first patient enrolled in phase 2a trial
AIVITA Biomedical AV-GBM-1 glioblastoma patient dosing complete in phase 2 trial
Amino Technology PalinGen Flow adults with chronic ulcers of the lower extremities due to venous stasis or diabetic etiologies initiation of phase 2 trial
NanOlogy NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection prostate cancer first patient enrolled in phase 2 trial
PolyActiva latanoprost-free-acid sustained-release ocular implant glaucoma initiation of phase 2 trial in Australia
Enlivix Allocetra sepsis approval received from the Israeli Ministry of Health for a phase 2b trial
Pfizer vupanorsen (AKCEA-ANGPTL3-LRx) patients with elevated nonhigh-density lipoprotein cholesterol (nonHDL-C) and triglycerides initiation of phase 2b trial
Asieris Pharmaceuticals APL-1202 nonmuscle-invasive bladder cancer approval granted by the Center for Drug Evaluation of the China National Medical Products Administration to initiate phase 3 trial
Cerevel Therapeutics tavapadon Parkinson’s disease first patients dosed in three phase 3 trials
Concert Pharmaceuticals CTP-543 moderate-to-severe alopecia areata initiation of phase 3 trial
Daiichi Sankyo

AstraZeneca		 Enhertu (fam-trastuzumab deruxtecan-nxki) adjuvant therapy in patients with HER2-positive early breast cancer with high risk of disease recurrence who have residual invasive disease in the breast or axillary lymph nodes after receiving neo-adjuvant therapy initiation of phase 3 trial
GW Pharmaceuticals

Greenwich Biosciences		 nabiximols multiple sclerosis-associated spasticity initiation of phase 3 trial
LianBio infigratinib locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions approval granted by the Center for Drug Evaluation of the China National Medical Products Administration to initiate phase 3 trial
Logic Bio LB-001 methylmalonic acidemia Fast-Track designation granted by the FDA
Rafael Pharmaceuticals CPI-613 (devimistat) soft tissue sarcoma Orphan Drug designation granted by the FDA
Boston Scientific Ranger drug-coated balloon patients with peripheral artery disease in the superficial femoral artery and proximal popliteal artery approved by the FDA
Chiesi, USA Bronchitol (mannitol) inhalation powder add-on maintenance therapy to improve pulmonary function in cystic fibrosis patients 18 years of age and older approved by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here